Hosted on MSN

Phase 2 trial reveals potential of DPP-1 inhibitor for bronchiectasis

In March 2025, The Lancet Respiratory Medicine published a phase 2 clinical study article on China's first DPP-1 inhibitor, HSK31858, led by Academician Nan-shan Zhong and Professor Wei-jie Guan from ...
MedPage Today

Novel DPP-1 Drug Trims Exacerbation Risk in Bronchiectasis

The ASPEN randomized trial showed that novel brensocatib cut the annualized rate of pulmonary exacerbations by around 20% compared with placebo. Brensocatib is a DPP-1 inhibitor that works by reducing ...
EurekAlert!

Breakthrough of DPP-1 Inhibitor in decreasing the exacerbation frequency of bronchiectasis (Lancet Respir Med)

Bronchiectasis is one of the most common highly heterogeneous chronic inflammatory airway diseases in China. It has a long course, heavy symptom burden, and is prone to recurrent acute exacerbations, ...
The Diplomat

For Taiwan’s DPP, an Unprecedented ‘3-peat’ Depends on a Third Party

With Taiwan’s January 2024 presidential elections fast approaching, the field of candidates has taken shape. From the incumbent Democratic Progressive Party (DPP), Vice President William Lai seeks to ...